We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
DxGen Corp.

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
03 Mar 2021 - 05 Mar 2021
Virtual Venue
06 Mar 2021 - 10 Mar 2021
Virtual Venue

A Rapid AI-based Screening Test for Prostate Cancer Biomarkers in Urine

By LabMedica International staff writers
Posted on 01 Feb 2021
Print article
Image: The 20-minute AI analysis detected prostate cancer in urine samples from 76 patients with greater than 99% accuracy (Photo courtesy of Korea Institute of Science and Technology)
Image: The 20-minute AI analysis detected prostate cancer in urine samples from 76 patients with greater than 99% accuracy (Photo courtesy of Korea Institute of Science and Technology)
A team of Korean investigators developed a highly accurate rapid technique for diagnosing prostate cancer based on AI (artificial intelligence) monitoring of urinary biomarkers.

Screening for prostate cancer generally relies on the serum prostate-specific antigen (PSA) test, which unfortunately generates a high rate of false positive results (up to 80%). This generates a large number of unnecessary biopsies with resultant unpleasant side effects, such as bleeding and pain. Considering how often the PSA test is used, there is a critical unmet need for a precision screening method for diagnosis of prostate cancer.

Toward this end, investigators at the Korea Institute of Science and Technology (Seoul) and their collaborators developed a technique for diagnosing the disease from urine by utilizing an electrical-signal-based ultrasensitive biosensor. The semiconductor sensor system was capable of simultaneously measuring trace amounts of four selected cancer factors in urine. The correlation of clinical state with the sensing signals from urinary biomarkers was analyzed by two common machine learning algorithms. As the number of biomarkers was increased, both algorithms provided a monotonic increase in screening performance.

When applied to urine samples from patients, the 20-minute AI analysis successfully detected 76 urinary samples with greater than 99% accuracy.

Senior author Dr. Kwan Hyi Lee, a principal research scientist at the Korea Institute of Science and Technology, said, "This research developed a smart biosensor that can rapidly diagnose prostate cancer with almost 100% accuracy only through a urine test, and it can be further utilized in the precise diagnoses of other cancers using a urine test."

The AI-based assay for diagnosis of prostate cancer was described in the December 9, 2020, online edition of the journal ACS Nano.

Related Links:
Korea Institute of Science and Technology

New
Gold Supplier
Nucleic Acid Extractor (Magnetic Bead Method)
Singu20
New
Gold Supplier
POC Analyzer
Epithod 616
COVID-19 and Influenza Test
COVID-19 and Influenza A+B Antigen Combo Rapid Test
COVID-19 Positive Control
STAT-NAT COVID-19 Positive Control

Print article

Channels

Industry

view channel
Image: Sysmex CN-Series automated blood coagulation analyzer (Photo courtesy of Sysmex Corporation)

Siemens and Sysmex Extend Agreement to Provide One of the Largest Portfolios of Hemostasis Testing Systems and Reagents

Siemens Healthineers (Erlangen, Germany) and Sysmex Corporation (Kobe, Japan) have renewed their long-standing global supply, distributorship, sales and service agreement for a broad portfolio of hemostasis... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.